Understanding Insulin Resistance with Intralipid and Palm Oil

This study aims to understand how different types of fats affect insulin resistance in muscles. Researchers will give participants either Intralipid or Palm Oil Emulsion through a tube into their small intestine overnight. On a separate day, you will also receive a saline (saltwater) infusion as a comparison. The main goal is to see how these fats change specific signaling molecules in muscle cells before and after a special test that measures how your body uses insulin (euglycemic, hyperinsulinemic clamp). This study is for healthy men and premenopausal women aged 18-55 with a BMI between 18-27. The study is currently unclear on its recruitment status and plans to enroll 60 participants.

Study design
This interventional study plans to enroll 60 participants. Each participant will receive Intralipid, Palm Oil Emulsion, and saline on separate days to compare their effects.
What's involved
Participants will receive overnight infusions of Intralipid, Palm Oil Emulsion, and saline through a tube into their small intestine. Measurements will be taken before and after a euglycemic, hyperinsulinemic clamp.
Compensation
Not stated in the trial record.
Follow-up
Changes in fatty acid enrichment will be measured at 18 hours after the euglycemic, hyperinsulinemic clamp.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03818178

Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

Recruiting
NAAges 18–55InterventionalBasic science
Mayo Clinic
~60 participants
Updated 2026-01-12 on ClinicalTrials.gov
What's tested:IntralipidPalm Oil EmulsionSaline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in fatty acid enrichment of intramyocellular signaling molecules before and after a euglycemic, hyperinsulinemic clamp
Measured over 18 hours
Insulin Resistance
1 sites across 1 states
Minnesota1
  • Michael D Jensen, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Women and Men (Women premenopausal)
BMI 18-27
Weight stable
Not pregnant/nursing

Exclusion

Ischemic heart disease
Atherosclerotic valvular disease
Smokers (\> 20 cigarettes per week)
Bilateral oophorectomy
Concomitant use of medications that can alter serum lipid profile (high dose fish oil, statins, niacin, fibrates, thiazolinediones, beta-blockers, atypical antipsychotics)
Lidocaine allergy
  • Change in fatty acid enrichment of intramyocellular signaling molecules before and after a euglycemic, hyperinsulinemic clamp18 hours

    The study involves the use of a hyperinsulinemic, euglycemic clamp to compare fatty acid enrichments in intramyocellular signaling molecules. The first half of the study will be the "pre-clamp" stage. During this stage, volunteers will receive an intravenous infusion of C13-labelled palmitate as a tracer in order for enrichment calculations to be performed pre-clamp. One muscle biopsy will be obtained to measure fatty acid enrichment within intramyocellular ceramides, diacylglycerols, long-chain acylcarnitines, and intramyocellular triglycerides. The insulin clamp will then commence, and volunteers will simultaneously receive an intravenous infusion of a second tracer, D-9 palmitate. This tracer will allow us to calculate enrichments during the insulin clamp stage of the study. A second muscle biopsy will be performed at the end of the insulin clamp, and similar enrichment calculations will be performed.